Skip to main content
Fig. 7 | Stem Cell Research & Therapy

Fig. 7

From: CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia

Fig. 7

Effects of blocked CD106+ BM-MSCs by a NF-κB-specific inhibitor on cord blood CD34+ cells. A,B CD106+ BM-MSCs from healthy controls (N) blocked by the NF-κB-specific inhibitor and then cocultured with sorted CD34+ cells. The percentage of CD34+ cells in the controls (a) and in the groups of blocked NF-κB at 0.5 h (b) and 1 h (c). C The number of colony-forming unit-granulocyte macrophage (CFU-GM), burst-forming unit-erythroid (BFU-E), and CFU mixed cell (CFU-GEMM) colonies was observed when purified CD34+ cells were cultured for 14 days in the controls and in the groups of blocked NF-κB at 0.5 h. ***P < 0.001 ****P<0.0001

Back to article page